US Stem Cell Inc (USRM)

[TheHungryHippo]

$USRM CHARTS / Positives Emerging & Deadlines Approaching.

1. This weeks sell volume was minuscule.
2. The 20 period Bollinger band is tightening and the bottom band is moving up quickly. This could be providing USRM additional support along with the 50 WMA moving average. So this will be a very strong level for support. imo.

.04s showed a lot of strength this week. it was too bad people sold into the bid on Friday.
but perhaps they are chasing other plays for now until USRM has some big events...

3. Daily Chart Parabolic SAR is at .0543 , this may come down and meet the price, creating a bullish SAR flip and short term uptrend... The 10 period Bands appear to be very tight. If we could somehow begin trading over the 10 day moving average, we would have a chance to break through the cloud to the upside back into the .07-.09 area. We have a lot of resistance to fight through in the .08 area due to the 50 dma being a resistance now. We will need a catalyst that brings in a lot of buy volume in order to achieve the 50 dma rising and becoming a support again.

With the possibility of RMAT still on the table in my opinion, I suspect the stock will begin to creep back up again in the next few weeks as the anticipation of the possibility of RMAT will draw nearer. If you read the CEO blogs carefully, and look throughout the entire internet, there is no where that shows any proof what-so-ever, that USRM has been rejected, or has received a decision about Myocell yet. The FDA 60 clock appears to have been reset two times putting our approximate window of a hearing a possible decision at the end of july or very early august.

USRM has recently been de-moralized by numerous authors of various internet media and postings who have twisted the wording from the company and made negative assumptions. However, the ones who have done their DD know that this company has a chance to have a very bright future. The recent panic drop down to .03 has done serious damage to the USRM chart and moral of the shareholders, but in my opinion USRM has a chance to recover here.

Someone here posted that Earnings were due in Early August. This is also what I suspect will be around the same time I would think that the FDA will deliver for Myocell, either:

(a) a positive or negative decision on RMAT
, or
(b) a request for more information.

By reading between the lines, and using common sense analysis, we can determine that this play is not over yet. With the new laws in the states shaping up in support of Stem Cell therapies being less regulated, and new clinics opening in numerous places throughout the country that will be adding revenues over the coming quarters-- this will serve as a good plan B should RMAT not come through.

As long as there is no extensive dilution, and the stock remains free of convertibles, I believe USRM will remain a good stock to remain long in, but With the possibility of RMAT being a variable that could change the stock price dramatically in either direction-- this will remain the main focus and unfortunately will continue to weigh in on the stock until a decision is announced.

Just my opinion. GLTA